FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995599191> ?p ?o ?g. }

• W1995599191 endingPage "3851" @default.
• W1995599191 startingPage "3837" @default.
• W1995599191 abstract "A novel N-¿2-amino-4-methyl[(pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl¿-L-glutamic acid (3a) was designed and synthesized as a potent dual inhibitor of thymidylate synthase (TS) and dihydrofolate reductase (DHFR) and as an antitumor agent. Compound 3b, the N7-benzylated analogue of 3a, was also synthesized as an antitumor agent. The synthesis of 3a was accomplished via a 12-step sequence which involved the synthesis of 2-amino-4-methylpyrrolo[2,3-d]pyrimidine (10) in 5 steps from 2-acetylbutyrolactone. Protection of the 2-amino group of 10 and regioselective iodination at the 5-position followed by palladium-catalyzed coupling afforded intermediate 14 which was converted to 3a by reduction and saponification. Similar synthetic methodology was used for 3b. X-ray crystal structure of the ternary complex of 3a, DHFR, and NADPH showed that the pyrrolo[2, 3-d]pyrimidine ring binds in a 2,4-diamino mode in which the pyrrole nitrogen mimics the 4-amino moiety of 2,4-diaminopyrimidines. This is the first example of a classical pyrrolo[2,3-d]pyrimidine antifolate shown to have this alternate mode of binding to DHFR. Compounds 3a and 3b were more inhibitory than LY231514 against TS from Lactobacillus casei and Escherichia coli. Analogue 3a was also more inhibitory against DHFR from human, Toxoplasma gondii, and Pneumocystis carinii. Evaluation of 3a against methotrexate (MTX)-resistant cell lines with defined mechanisms indicated that cross-resistance of 3a was much lower than that of MTX. Metabolite protection studies and folylpoly-gamma-glutamate synthetase studies suggest that the antitumor activity of 3a against the growth of tumor cells in culture is a result of dual inhibition of TS and DHFR. Compound 3a inhibited the growth of CCRF-CEM and FaDu cells in culture at ED(50) values of 12.5 and 7.0 nM, respectively, and was more active against FaDu cells than MTX. In contrast, compound 3b was inactive against both cell lines. Compound 3a was evaluated in the National Cancer Institute in vitro preclinical antitumor screening program and afforded IG(50) values in the nanomolar range against a number of tumor cell lines." @default.
• W1995599191 created "2016-06-24" @default.
• W1995599191 creator A5010182365 @default.
• W1995599191 creator A5052492275 @default.
• W1995599191 creator A5052708209 @default.
• W1995599191 creator A5055670356 @default.
• W1995599191 creator A5071627490 @default.
• W1995599191 creator A5088782676 @default.
• W1995599191 creator A5091214681 @default.
• W1995599191 date "2000-09-13" @default.
• W1995599191 modified "2023-09-25" @default.
• W1995599191 title "Design, Synthesis, and X-ray Crystal Structure of a Potent Dual Inhibitor of Thymidylate Synthase and Dihydrofolate Reductase as an Antitumor Agent" @default.
• W1995599191 cites W1482352151 @default.
• W1995599191 cites W1600598432 @default.
• W1995599191 cites W1966633783 @default.
• W1995599191 cites W1976438130 @default.
• W1995599191 cites W1982669395 @default.
• W1995599191 cites W1984527244 @default.
• W1995599191 cites W1986191025 @default.
• W1995599191 cites W1989041902 @default.
• W1995599191 cites W1990658138 @default.
• W1995599191 cites W2001448929 @default.
• W1995599191 cites W2003542356 @default.
• W1995599191 cites W2006416369 @default.
• W1995599191 cites W2010485888 @default.
• W1995599191 cites W2013509971 @default.
• W1995599191 cites W2020159902 @default.
• W1995599191 cites W2021215424 @default.
• W1995599191 cites W2022689643 @default.
• W1995599191 cites W2029125742 @default.
• W1995599191 cites W2030517889 @default.
• W1995599191 cites W2031035868 @default.
• W1995599191 cites W2031825904 @default.
• W1995599191 cites W2035710274 @default.
• W1995599191 cites W2046441811 @default.
• W1995599191 cites W2050151473 @default.
• W1995599191 cites W2053963992 @default.
• W1995599191 cites W2059614919 @default.
• W1995599191 cites W2068859667 @default.
• W1995599191 cites W2074713052 @default.
• W1995599191 cites W2081091078 @default.
• W1995599191 cites W2081532044 @default.
• W1995599191 cites W2083152170 @default.
• W1995599191 cites W2086863971 @default.
• W1995599191 cites W2094467922 @default.
• W1995599191 cites W2176123637 @default.
• W1995599191 cites W2951200084 @default.
• W1995599191 doi "https://doi.org/10.1021/jm000200l" @default.
• W1995599191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11052789" @default.
• W1995599191 hasPublicationYear "2000" @default.
• W1995599191 type Work @default.
• W1995599191 sameAs 1995599191 @default.
• W1995599191 citedByCount "68" @default.
• W1995599191 countsByYear W19955991912012 @default.
• W1995599191 countsByYear W19955991912013 @default.
• W1995599191 countsByYear W19955991912014 @default.
• W1995599191 countsByYear W19955991912015 @default.
• W1995599191 countsByYear W19955991912017 @default.
• W1995599191 countsByYear W19955991912018 @default.
• W1995599191 countsByYear W19955991912019 @default.
• W1995599191 countsByYear W19955991912020 @default.
• W1995599191 countsByYear W19955991912021 @default.
• W1995599191 countsByYear W19955991912022 @default.
• W1995599191 countsByYear W19955991912023 @default.
• W1995599191 crossrefType "journal-article" @default.
• W1995599191 hasAuthorship W1995599191A5010182365 @default.
• W1995599191 hasAuthorship W1995599191A5052492275 @default.
• W1995599191 hasAuthorship W1995599191A5052708209 @default.
• W1995599191 hasAuthorship W1995599191A5055670356 @default.
• W1995599191 hasAuthorship W1995599191A5071627490 @default.
• W1995599191 hasAuthorship W1995599191A5088782676 @default.
• W1995599191 hasAuthorship W1995599191A5091214681 @default.
• W1995599191 hasConcept C123321153 @default.
• W1995599191 hasConcept C141071460 @default.
• W1995599191 hasConcept C178790620 @default.
• W1995599191 hasConcept C181199279 @default.
• W1995599191 hasConcept C185592680 @default.
• W1995599191 hasConcept C2776694085 @default.
• W1995599191 hasConcept C2778397455 @default.
• W1995599191 hasConcept C2779321679 @default.
• W1995599191 hasConcept C2780456651 @default.
• W1995599191 hasConcept C2781320022 @default.
• W1995599191 hasConcept C2781382166 @default.
• W1995599191 hasConcept C29730261 @default.
• W1995599191 hasConcept C55493867 @default.
• W1995599191 hasConcept C71240020 @default.
• W1995599191 hasConcept C71924100 @default.
• W1995599191 hasConceptScore W1995599191C123321153 @default.
• W1995599191 hasConceptScore W1995599191C141071460 @default.
• W1995599191 hasConceptScore W1995599191C178790620 @default.
• W1995599191 hasConceptScore W1995599191C181199279 @default.
• W1995599191 hasConceptScore W1995599191C185592680 @default.
• W1995599191 hasConceptScore W1995599191C2776694085 @default.
• W1995599191 hasConceptScore W1995599191C2778397455 @default.
• W1995599191 hasConceptScore W1995599191C2779321679 @default.
• W1995599191 hasConceptScore W1995599191C2780456651 @default.
• W1995599191 hasConceptScore W1995599191C2781320022 @default.
• W1995599191 hasConceptScore W1995599191C2781382166 @default.

• next